MOUNTAIN VIEW, Calif., Nov. 18 With the launch of several companion diagnostics over the past year, we have officially entered the personalized medicine era. These diagnostics and follow-on therapeutics utilize molecular analysis technologies to diagnose and manage a patient's disease or predisposition towards a disease. The ultimate goal is to prescribe a therapeutic plan tailored to an individual's genetics and environmental profile. While revenues from companion diagnostics are just starting to trickle in, the push towards personalized medicine is driving several markets along the pipeline of drug discovery. From "bench to bedside," this healthcare trend continues to spur basic research technologies, biomarker discovery, pharmacogenomics services, and of course, companion diagnostics and therapeutics.
To view the Multimedia News Release, go to: http://multivu.prnewswire.com/mnr/frostsullivan/39847/
"It's important to understand that personalized medicine encompasses many disparate markets; it might relate to pharmaceutical companies' drug pipelines, the development of new diagnostic tests, or the sales of innovative technologies for biomedical research," explains Frost & Sullivan Industry Analyst, Christi Bird. "To appropriately evaluate the extent to which personalized medicine is actually driving revenues, we need to define the multiple market microcosms that are the foundation of personalized medicine -- anything from services for biomarker discovery to companion diagnostics for guiding therapy decisions."
Several new studies from Frost & Sullivan analyze the markets surrounding personalized medicine. Frost & Sullivan's Drug Discovery Technologies & Clinical Diagnostics team (http://drugdiscovery.frost.com) recently launched the following studies related to personalized medicine:
In the near future, the firm plans to conduct analyses of additional personalized medicine markets:
In addition, Frost & Sullivan's Pharmaceutical & Biotechnology team (http://pharma.frost.com) recently launched:
If you are interested in additional information on any of these studies, or if you wish to speak with Frost & Sullivan's analysts, please send an e-mail to Johanna Haynes, Corporate Communications, at email@example.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.
"While the process of moving basic research to a final clinical product used by physicians to administer personalized care is extremely time-consuming and challenging, the launch of several companion diagnostics demonstrates that it can be done," adds Bird. "These achievements reduce the risk associated with entering markets related to personalized medicine, and thus, will spur even greater growth in these markets in the near future."
All market analyses mentioned are a part of Frost & Sullivan's Drug Discovery Technologies, Clinical Diagnostics, or Pharmaceutical & Biotechnology Growth Partnership Services program. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
-- U.S. Cancer Molecular Diagnostics -- Strategic Analysis of U.S. Molecular Cytogenetics Markets -- U.S. MicroRNA Markets -- U.S. Nucleic Acid Purification and Isolation Markets -- Strategic Analysis of U.S. MicroRNA Services Markets -- U.S. Molecular Diagnostics Markets for Emerging Infectious Disease Tests
SOURCE Frost & Sullivan